Clinical Trials
Page 4 • 12 itemsAccess global clinical trial data, regulatory updates, and competitive intelligence for strategic pharma R&D and investment decisions.
Calluna Pharma Completes CAL101 Phase 2 Enrollment for Idiopathic Pulmonary Fibrosis Treatment
Calluna Pharma enrolls 161 patients in Phase 2 AURORA study of CAL101 for IPF treatment, six months ahead of schedule with topline data expected Q1 2027.
Anixa Biosciences Lira-cel CAR-T Therapy Shows Positive Survival Data in Ovarian Cancer Phase 1 Trial
Anixa Biosciences announces positive survival data for Lira-cel CAR-T therapy in ovarian cancer Phase 1 trial, with presentation at ISCT 2026 meeting.
Hengrui Pharma Q1 2026 Results: Anti-PD-L1/TGF-βRII Fusion Protein Approved in China
Hengrui Pharma reports Q1 2026 growth with three innovative drug approvals including breakthrough anti-PD-L1/TGF-βRII bi-functional fusion protein in China.
Alphamab Oncology JSKN016 TROP2/HER3 Bispecific ADC Shows Promise for HER2-Negative Breast Cancer at ASCO 2026
Alphamab Oncology presents clinical data for JSKN016, a novel TROP2/HER3 bispecific ADC targeting HER2-negative breast cancer at ASCO 2026 conference.
Kelun-Biotech's Sacituzumab Tirumotecan and Two Other Cancer Drugs Selected for ASCO 2026 Oral Presentations
Kelun-Biotech announces three clinical studies selected for oral presentations at ASCO 2026, including TROP2 ADC sacituzumab tirumotecan results.
NOVI Health's Hybrid Care Model Bridges GLP-1 Drug Efficacy Gap Between Clinical Trials and Real-World Outcomes
NOVI Health introduces hybrid care approach to improve real-world GLP-1 obesity drug outcomes that typically underperform compared to clinical trials.
Suvoda Launches Agentic AI-Powered RTSM System, Reduces Clinical Trial Startup Time by 80%
Suvoda's new agentic RTSM uses AI to cut clinical trial startup timelines by up to 80%, accelerating drug development and patient access to treatments.
Dayspring Pharma's CG2001 Foam Meets Primary Endpoint in Phase II Male Pattern Baldness Trial
Dayspring Pharma announces positive Phase II results for CG2001 foam in treating male pattern baldness, showing significant efficacy in Chinese men.
PeptiDream Partner Asahi Kasei Therapeutics Initiates Phase 1 Clinical Trial for AK1940
Asahi Kasei Therapeutics begins Phase 1 clinical trial for AK1940, developed through collaboration with PeptiDream Inc., marking key milestone in drug development.
Rznomics RZ-001 Shows 61.5% Response Rate in Hepatocellular Carcinoma Trial at AACR 2026
Rznomics reports encouraging interim data for RZ-001 RNA editing therapy in liver cancer, showing 61.5% response rate with favorable safety profile at AACR 2026.
Biogen Acquires Felzartamab Rights from TJ Biopharma for Greater China Market
Biogen consolidates global felzartamab rights through strategic acquisition from TJ Biopharma, expanding CD38-directed antibody reach in China market.
Argo Biopharma Begins Phase II Trials of BW-40202 siRNA Therapy for Rare Kidney Diseases
Argo Biopharma doses first patients in Phase II trials of BW-40202, an investigational siRNA therapy targeting complement factor B for PNH and IgAN treatment.